JP2021522795A5 - - Google Patents
Info
- Publication number
- JP2021522795A5 JP2021522795A5 JP2020561780A JP2020561780A JP2021522795A5 JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5 JP 2020561780 A JP2020561780 A JP 2020561780A JP 2020561780 A JP2020561780 A JP 2020561780A JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- item
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666548P | 2018-05-03 | 2018-05-03 | |
| US62/666,548 | 2018-05-03 | ||
| US201862779992P | 2018-12-14 | 2018-12-14 | |
| US62/779,992 | 2018-12-14 | ||
| PCT/US2019/030475 WO2019213446A1 (en) | 2018-05-03 | 2019-05-02 | NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522795A JP2021522795A (ja) | 2021-09-02 |
| JP2021522795A5 true JP2021522795A5 (enExample) | 2022-05-13 |
Family
ID=68386156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561780A Pending JP2021522795A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12168683B2 (enExample) |
| EP (1) | EP3788067A4 (enExample) |
| JP (1) | JP2021522795A (enExample) |
| AU (1) | AU2019262143A1 (enExample) |
| CA (1) | CA3099325A1 (enExample) |
| WO (1) | WO2019213446A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019262139A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Multispecific binders of TGFβ-superfamily ligands and uses thereof |
| US12527839B2 (en) | 2019-11-05 | 2026-01-20 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| CA3232382A1 (en) * | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof |
| KR102971166B1 (ko) * | 2022-12-09 | 2026-06-01 | (주)케어젠 | 연골 재생용 펩타이드 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008113185A1 (en) * | 2007-03-19 | 2008-09-25 | National Research Counsil Of Canada | Antagonists of ligands and uses thereof |
| US8993524B2 (en) * | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| RU2678117C2 (ru) * | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| HK1225742A1 (zh) * | 2013-08-22 | 2017-09-15 | Acceleron Pharma, Inc. | TGF-β受体II型变体及其用途 |
| HRP20210977T1 (hr) * | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| JP6631865B2 (ja) * | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| EP3280435B1 (en) | 2015-04-06 | 2021-06-02 | Acceleron Pharma Inc. | Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| EP3522912A4 (en) | 2016-10-05 | 2020-10-14 | Acceleron Pharma Inc. | HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES |
| CN110678195A (zh) | 2016-10-05 | 2020-01-10 | 阿塞勒隆制药公司 | ALK4:ActRIIB异多聚体及其用途 |
-
2019
- 2019-05-02 EP EP19796602.1A patent/EP3788067A4/en active Pending
- 2019-05-02 AU AU2019262143A patent/AU2019262143A1/en not_active Abandoned
- 2019-05-02 US US17/052,783 patent/US12168683B2/en active Active
- 2019-05-02 CA CA3099325A patent/CA3099325A1/en active Pending
- 2019-05-02 JP JP2020561780A patent/JP2021522795A/ja active Pending
- 2019-05-02 WO PCT/US2019/030475 patent/WO2019213446A1/en not_active Ceased
-
2024
- 2024-10-23 US US18/924,487 patent/US20250333477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3218411B1 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| JP2022523524A5 (enExample) | ||
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2021175391A5 (enExample) | ||
| CN119569850A (zh) | 激活素受体iia型变体及其使用方法 | |
| JP2023554500A5 (enExample) | ||
| JP7793774B2 (ja) | メソテリン結合タンパク質及びその使用 | |
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JP2021522793A5 (enExample) | ||
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2023522799A5 (enExample) | ||
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2024504923A5 (enExample) | ||
| JP2022540918A5 (enExample) | ||
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| AU2022316521B2 (en) | A fusion protein comprising an antigen binding domain and a cytokine trimer domain | |
| JP2025524899A (ja) | メソテリン結合タンパク質及びその使用 | |
| CN117295758A (zh) | 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白 | |
| WO2022226352A1 (en) | Kidney-glomerular targeted immunotherapy | |
| JP7829127B2 (ja) | 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質 | |
| JP2024537397A5 (enExample) | ||
| WO2026037338A1 (zh) | 一种阻断baff、april作用其受体的融合蛋白 | |
| WO2025228408A1 (zh) | Ghr激动型抗体及其应用 | |
| CN118119402A (zh) | 工程化抗her2双特异性蛋白 | |
| CA3196077A1 (en) | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof |